Overview

A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.
Phase:
Phase 2
Details
Lead Sponsor:
BioLineRx, Ltd.
Treatments:
Risperidone